The purpose of this research was to develop a solid dispersion and a nanosuspension to improve gefitinib's solubility, and then evaluate and compare their efficacies. The SDS and NSP were prepared using solvent evaporation and precipitation methods respectively. Evaporating a hydro-alcoholic solution of GFT and HPMC at an optimum ratio (1: 5 w/w) yielded solid dispersions of GFT. A sufficient quantity of ethanol was used to dissolve the polymer. 32 complete factorial designs were used to optimize the NSP. Independent factors were Polo-188 (X1) and Tween-80 (X2), while dependent variables included polydispersity index (Y1) and particle size (Y2). The nine batches of NSP and SDS were created by adjusting the concentrations of the excipients. The drug concentration of NSP batches was found to be between 81.31 and 96.71%, with NSP 6 demonstrating the highest drug level of any batch tested, at 96.71%. SDS-7 had a PS of 251.7 nm, whereas NSP-6's PS was 131.8 nm. It was shown that although HPMC demonstrated a small solubility increase in the property of SDS-7 in all solvents, the most advanced NSP-6 formulation benefited from Polo-188's solubility augmentation. The results of this research indicate that gefitinib solubility was improved by the preparation of a nanosuspension.